Utilization of Interferon in Gynecologic and Breast Cancer

Nomelini, Rosekeila Simões; Mardegan, Marília De Carvalho; Murta, Eddie Fernando Cândido

doi:10.4137/cmo.s432

Cited by 3 publications

(3 citation statements)

References 86 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the early 1980s, several studies have used interferon in the treatment of gynecological cancer with different responses [ 13 ]. In the case of interferon-α, some studies show remission of cervical intraepithelial neoplasia, ranging from 30% to 80% of cases [ 14 , 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α

Michelin

Montes

Nomelini

et al. 2015

IJMS

View full text Add to dashboard Cite

Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4+) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4+ T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4+ T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4+ T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern.

show abstract

Section: Discussionmentioning

confidence: 99%

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α

Michelin

Montes

Nomelini

et al. 2015

IJMS

View full text Add to dashboard Cite

show abstract

“…Since the early 1980s, several studies have used interferon to treat gynecological cancer [96]. Interferons (IFNs) are glycoproteins that were initially described with antiviral effects [97].…”

Section: Immunotherapy In Premalignant Cervical Lesionsmentioning

confidence: 99%

Immune response in cervical intraepithelial neoplasms

2021

EJGO

View full text Add to dashboard Cite

The current study aims perform a comprehensive overview of the topic immune response in cervical intraepithelial neoplasms, summarizing the findings of literature. Data sources: PubMed database. Methods of study selection: A search for the following descriptors was performed in the PubMed database: descriptor ''immune response in cervical cancer and Human Papilloma Virus (HPV)''; ''immunotherapy in premalignant cervical lesions'' . Tabulation, integration and results: The articles identified were published between 1967 and 2021. We selected 85 articles for review on the subject (reference 16 onwards). This literature review shows the important role that the immune system plays in the development and progression of cervical cancer. Immune response in pre-neoplastic cervical lesions includes host defense mechanisms against the HPV, adaptive immunity and the function of cytokines. Predictive factors of viral persistence and progression of premalignant lesions may also be associated with immune response. Conclusion: One of the determining factors for the persistence or elimination of HPV infections and their evolution to pre-neoplastic lesions is the cellular immune response, as the progression or regression of the tumor depends on the type and amount of cytokines secreted by the body. The investigation of these immune reactions may provide new therapeutic targets for cervical intraepithelial neoplasms.

show abstract

“…In breast cancer, type I Interferons have been used in receptor-positive cases. When the tumor becomes resistant, one option is treatment with interferon in combination with tamoxifen, IL-2 or other chemotherapeutic drugs; some good results have been obtained, but it is necessary to consider the toxicity and side effects of these treatments (6). TNBC is a heterogeneous group of different treatment-resistant neoplasms with different prognosis.…”

mentioning

confidence: 99%

Interferon-tau (IFN-τ) Has Antiproliferative Effects, Induces Apoptosis, and Inhibits Tumor Growth in a Triple-negative Breast Cancer Murine Tumor Model

ESPIN-RIVERA,

MEZA-APARICIO,

REYNA-FLORES

et al. 2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: Resistant triple-negative breast cancer (TNBC) is a subtype of this disease that is resistant to conventional chemotherapy agents. IFN-τ is a cytokine that has recently been shown to have immunoregulatory and antitumor effects. The present study aimed to examine the antiproliferative and apoptosis effects of IFN-τ in breast cancer cells and the antitumor effect in a murine tumor model of TNBC. Materials and Methods: Murine breast cancer 4T1 cells were cultured and treated with ovine IFNτ and through MTT and Caspase-Glo 3/7 assays, viability and cell death were determined. In addition, the antitumor effect of IFN-τ was determined in a murine tumor model of TNBC. Results: Ovine IFN-τ showed a concentrationdependent antiproliferative effect on 4T1 murine breast cancer cells. Also, treatment of 4T1 cells with IFN-τ induced the activation of caspase 3 and 7, which is indicative of apoptotic cell death. Moreover, we detected an increase in the expression of type I interferon receptor (IFNAR1/2) in cells treated with IFN-. The intratumoral application of IFN-τ in mice inhibited tumor growth compared to the control nontreated group, and the effect was associated with the increased expression of GM-CSF. Conclusion: Ovine IFN-τ may be an effective immunotherapeutic cytokine for the treatment of TNBC.

show abstract

Utilization of Interferon in Gynecologic and Breast Cancer

Cited by 3 publications

References 86 publications

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α

Immune response in cervical intraepithelial neoplasms

Interferon-tau (IFN-τ) Has Antiproliferative Effects, Induces Apoptosis, and Inhibits Tumor Growth in a Triple-negative Breast Cancer Murine Tumor Model

Contact Info

Product

Resources

About